Who is sponsoring NCT03602911?

NCT03602911 is sponsored by West Virginia University.

What drugs are being tested in NCT03602911?

Interventions in NCT03602911: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT.

What condition does NCT03602911 study?

NCT03602911 studies Head and Neck Squamous Cell Carcinoma.

Is NCT03602911 still recruiting?

NCT03602911 is currently completed. Last updated 12 March 2025.

Are results published for NCT03602911?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-12 · How we verify

NCT03602911

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

Completed Phase 2 Results posted Last updated 12 March 2025

What this trial tests

Phase 2 trial testing The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma in 20 participants. Completed in 1 April 2021.

Timeline

1 February 2019

Primary endpoint
1 April 2021

1 April 2021

Quick facts

Lead sponsor	West Virginia University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	1 February 2019
Primary completion	1 April 2021
Estimated completion	1 April 2021
Sites	1 location across United States

Drugs / interventions tested

The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →

Sponsor

West Virginia University

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Detection and Staging of Head and Neck Squamous Cell Carcinoma Using Standard Uptake Value for NETSPOT Imaging Primary · From Baseline up to day 7 post imaging

NETSPOT imaging will be at least equivalent to 18F FDG PET/CT in the detection and staging of HNSCC. This will be done using Standard Uptake Value (SUV) measurements. SUV max of \> 2.5 for 18F-FDG-PET and \> 1.5 for 68GA DOTATATE-PET/CT were used as thresholds of concern. Using the PET scan, investigators calculated the standard uptake value (SUV), to compare the amount of an agent injected into the patient and the amount taken up by the tumor.

OP-Primary Tumor

Group	Value	95% CI
Proof of Concept	7.21	± 17.00

OP-Nodes

Group	Value	95% CI
Proof of Concept	4.84	± 17.00

OC-Primary Tumor

Group	Value	95% CI
Proof of Concept	2.87	± 17.00

OC-Nodes

Group	Value	95% CI
Proof of Concept	2.46	± 17.00

Larynx-Nodes

Group	Value	95% CI
Proof of Concept	3.24	± 17.00

Detection of Primary Site for Head and Neck Squamous Cell Carcinoma Using SUV Measurements With NETSPOT Imaging Secondary · From Baseline up to day 7 post imaging

The Combination of NETSPOT imaging and 19F FDG PET/CT will have increased specificity for detecting the primary site for HNSCC of unknown primary than 18F FDG PET/CT alone. This will be done using Standard Uptake Value (SUV) measurements. SUV max of \> 2.5 for 18F-FDG-PET and \> 1.5 for 68GA DOTATATE-PET/CT were used as thresholds of concern. Using the PET scan, radiologists can calculate the standard uptake value (SUV), to compare the amount of an agent injected into the patient and the amount taken up by the tumor.

OP-Primary Tumor

Group	Value	95% CI
Proof of Concept	14.98	± 18.25

OP-Nodes

Group	Value	95% CI
Proof of Concept	7.59	± 18.25

OC-Primary Tumor

Group	Value	95% CI
Proof of Concept	13.11	± 18.25

OC-Nodes

Group	Value	95% CI
Proof of Concept	5.96	± 18.25

Larynx-Nodes

Group	Value	95% CI
Proof of Concept	3.92	± 18.25

Sponsor's own description

This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other West Virginia University trials

Trials by the same sponsor.

NCT06686914 — The Effects of Cannabidiol on the Driving Performance of Healthy Adults by Dose and Sex · Phase 1 · recruiting
NCT06791850 — Sustaining Home Heart Failure Palliative Care in Rural Appalachia · NA · recruiting
NCT05705999 — Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study · NA · recruiting
NCT05353244 — Effects of PrTMS on Performance · NA · withdrawn
NCT06612788 — Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03602911 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West Virginia University
Last refreshed: 12 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03602911.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing